網(wǎng)站介紹 關(guān)于我們 聯(lián)系方式 廣告業(yè)務(wù) 幫助信息
1998-2021 ChinaKaoyan.com Network Studio. All Rights Reserved. 滬ICP備12018245號(hào)
2025考研復(fù)試特訓(xùn)班【1v1個(gè)性批改+模擬面試+聽口糾音】
一 研究生調(diào)劑信息:
1 今年擬招調(diào)劑研究生3名,主要從事腫瘤分子遺傳學(xué)及表觀遺傳學(xué)研究
2 待遇:
(1)在校期間可以享受學(xué)校提供的各種助學(xué)金(相當(dāng)于以往的公費(fèi)錄。。
(2)除學(xué)校提供的生活補(bǔ)貼外,導(dǎo)師根據(jù)學(xué)生表現(xiàn)每月提供700-1000的勞務(wù)補(bǔ)貼。
(3)學(xué)校提供各類獎(jiǎng)學(xué)金,最高可達(dá)2萬元。
3 錄取要求
(1)原則上總分?jǐn)?shù)、單科須過國家分?jǐn)?shù)線。
(2)對(duì)本實(shí)驗(yàn)室研究感興趣,吃苦耐勞。
4 聯(lián)系方式: tangkaifu@hotmail.com
二 唐開福課題組介紹
(1)本實(shí)驗(yàn)室?guī)熧Y力量雄厚
目前師生比例1:3。本課題組目前共有研究人員9名,包括3個(gè)老師(唐開福教授、吳建民副教授和李桂玲副教授)和6個(gè)研究生,吳建民副教授和李桂玲副教授協(xié)助唐開福教授指導(dǎo)研究生。
課題組3個(gè)老師都在國外從事相關(guān)研究多年:唐開福博士曾在德國和瑞士留學(xué)5年;李桂玲博士在美國和歐洲留學(xué)10年,吳建民博士曾在美國留學(xué)2年。
(2)課題組經(jīng)費(fèi)充足
唐開福目前承擔(dān)項(xiàng)目見其簡(jiǎn)介;李桂玲博士目前承擔(dān)“863”重大項(xiàng)目子課題1項(xiàng)、國家自然科學(xué)基金1項(xiàng);吳建民博士承擔(dān)國家自然科學(xué)基金等共3項(xiàng)。
(3)研究生培養(yǎng)質(zhì)量?jī)?yōu)良
本課題組師生比例一直維持在1:3-1:4之間,按精英模式培養(yǎng)。已畢業(yè)研究生的質(zhì)量得到了國內(nèi)外高校認(rèn)可,畢業(yè)生大多去了國內(nèi)外一流大學(xué)及研究所(如清華大學(xué)、NIBS等)工作。
(4)課題組長唐開福簡(jiǎn)介
1972年3月出生,博士,溫州醫(yī)科大學(xué)基因組醫(yī)學(xué)研究院研究員。兼任溫州醫(yī)科大學(xué)附屬第一醫(yī)院感染科教授、肝病研究所副主任。浙江省杰出青年基金獲得者(2011年);浙江省151人才工程第三層次培養(yǎng)人員(2011年);浙江省151人才工程第二層次培養(yǎng)人員(2012年);溫州市551第一層次培養(yǎng)人員;《Frontiers in Gastrointestinal Cancers》編委;World Journal of Biological Chemistry編委;BIT'S 3rd Annual world DNA and Genome Day 顧問委員會(huì)成員;《中華肝臟病雜志》通訊編委;教育部創(chuàng)新團(tuán)隊(duì)成員。近5年以來主持國家自然科學(xué)基金4項(xiàng)、其他項(xiàng)目共7項(xiàng);作為骨干參與艾滋病和病毒性肝炎等重大傳染病防治專項(xiàng)1項(xiàng);參加國家自然科學(xué)基金8項(xiàng)。獲得各類人才項(xiàng)目共4項(xiàng)。獲重慶市科技進(jìn)步一等獎(jiǎng)、教育部科技進(jìn)步二等獎(jiǎng)、中華醫(yī)學(xué)科技獎(jiǎng)二等獎(jiǎng)等共6項(xiàng)。發(fā)表文章50余篇。
部分文章及專著(*為通訊作者,IF為近5年平均影響因子)
1 Wu J, Zhang XJ, Shi KQ, Chen YP, Ren YF, Song YJ, Li G, Xue YF, Fang YX, Deng ZJ, Xu X, Gao J, Tang KF*. Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells. Carcinogenesis. 35(1):155-63. 2014. ( IF=5.557)
2 Tang KF*, Ren H, Cao J, Zeng GL, Xie J, Chen M, Wang L, He CX. Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol. 182(2):233-9. 2008. (IF=10.367)
3 Wu J, Wu g, Lv L, R YF, Zhang XJ, Xue YF, Li G, Lu XC, Sun ZS, Tang KF*. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 33(3):519-28. 2012. ( IF=5.557)
4 Ren YF, Li G, Xue YF, Zhang XJ, Song YJ, Lv L, Wu J, Fang YX, Wang YQ, Shi KQ, Chen YP, Tang KF*. Decreased dicer expression enhances SRP-mediated protein targeting. PLoS One. 8(2):e56950. 2013. (IF=4.244)
5 Ren YF, Li G, Wu J, Xue YF, Song YJ, LV L, Zhang XJ, Tang KF*. Dicer-Dependent Biogenesis of Small RNAs Derived from 7SL RNA. PLoS One. 7(7):e40705. 2012. (IF=4.244)
6 Tang KF, Song GB*, Shi YS, Yuan L, Li YH. Dicer knockdown induces fibronectin-1 expression in HEK293T cells via induction of Egr1. Biochim Biophys Acta. 1800(3):380-4.2010. ( IF=4.204)
7 Tang KF*, Wang Y, Wang P, Chen M, Chen Y, Hu HD, Hu P, Wang B, Yang W, Ren H*. Upregulation of PHLDA2 in Dicer knockdown HEK293 cells. Biochim Biophys Acta. 1770(5):820-5. 2007. ( IF=4.204)
8 Sun XR, Wu, Shi KQ, Tang KF*. Relationship between IL-10 gene -1082A/G and -592C/A polymorphisms and the risk of hepatitis C infection: a meta-analysis. J Viral Hepat. 20(9):602-11. 2013. ( IF=3.251)
9 Tang KF*, Chen M, Xie J, Song GB, Shi YS, Liu Q, Mei ZC, Steinle A, Ren H*. Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. Med Microbiol Immunol. 198 (1): 27-32. 2009. ( IF=3.278)
10 Tang KF*, He CX, Zeng GL, Wu J, Song GB, Shi YS, Zhang WG, Huang AL, Steinle A, Ren H*. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun. 370(4):578-83. 2008. ( IF=2.5)
11 Wu JF, Shen W, Liu NZ, Zeng GL, Yang M, Zuo GQ, Gan XN, Ren H, Tang KF*. Down-regulation of Dicer in hepatocellular carcinoma. Med Oncol. 28(3):804-9. 2011. (IF=1.96)
12 Tang KF*, Xie J, Chen M, Liu Q, Zhou XY, Zeng W, Huang AL, Zuo GQ, Wang Y, Xiang R, Ren H*. Knockdown of damage-specific DNA binding protein 1 (DDB1) enhances the HBx-siRNA-mediated inhibition of HBV replication. Biologicals. 36(3):177-83. 2008. (IF=1.538)
13 Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, Fang YX, Li GL, Song YJ, Deng ZJ, Wu JM, Tang KF*. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014 Jan 29. doi: 10.1111/jgh.12519. [Epub ahead of print]. (IF=3.08)
14 Li G, Li DW, Fang YX, Song YJ, Deng ZJ, Gao J, Xie Y, Yin TS, Ying L*, Tang KF*. Performance of shear wave elastography for differentiation of benign and malignant solid breast masses. PLoS One. 8(10):e76322. 2013. (IF=4.244)
15 Shi KQ, Lin Z, Li DW, Fang YX, Gao J, Deng ZJ, Chen L, Li GL, Wu JM, Tang KF*. Meta-analysis of the association between a polymorphism in microRNA-196a2 and susceptibility to colorectal cancer. Onkologie. 36(10):560-5. 2013. (IF=1.031)
16 Ying L, Lin X, Xie ZL, Hu YP, Tang KF*, Shi KQ*. Clinical utility of endoscopic ultrasound elastography for identification of malignant pancreatic masses: a meta-analysis. J Gastroenterol Hepatol. 28(9):1434-43. 2013. (IF=3.08)
17 Deng ZJ, Shi KQ, Song YJ, Fang YX, Wu J, Li G, Tang KF, Qu J*. Association between a Lumican Promoter Polymorphism and High Myopia in the Chinese Population: A Meta-Analysis of Case-Control Studies. Ophthalmologica. 2014 Feb 8. [Epub ahead of print]. (IF=1.236)
18 Tang KF*, Ren H*. The role of dicer in DNA damage repair. Int J Mol Sci. 13(12):16769-78.2012. (IF=2.732)
19 Hu P, Hu HD, Chen M, Peng ML, Tang L, Tang KF, Matsui M, Belladonna ML, Yoshimoto T, Zhang DZ, Xiang R, Ren H*. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol. 46(8-9):1654-62. 2009. (IF=2.917)
20 Chen M, Zhang D, Zhen W, Shi Q, Liu Y, Ling N, Peng M, Tang K, Hu P, Hu H, Ren H*. Characteristics of circulating TCRγδT cells from individuals chronically infected with HBV: an association between Vδ2T subtype and chronic HBV infection. J Infect Dis. 198(11):1643-50. 2008. (IF= 5.914)
21 Sun XR, Wu J, Tang KF*. The interferon-gamma (IFN-y) +874T allele reduces
the risk of hepatitis B infection in an Asian population. J Viral Hepat, (In press) ( IF=3.251).
22 Hu P, Peng ML, Chen M, Hu HD, Tang L, Tang KF, Ren H*. (2009)Molecular cloning, expression and characterization of an interleukin 27 p28 homolog in pig (Sus scrofa).Vet Immunol Immunopathol. 130(3-4):262-7. IF=2.163.
23 Shi N, Zhou W, Tang K, Gao Y, Jin J, Gao F, Peng X, Bartlam M, Qiang B*, Yuan J*, Rao Z*. Expression, crystallization and preliminary X-ray studies of the recombinant PTB domain of human dok-5 protein. Acta Crystallogr D Biol Crystallogr. 2002 Dec;58(Pt 12):2170-2. IF=7.54
24 Yu-Qun Wang 1,2#, Yong-Feng Ren 1#, Yi-Jiang Song 1#, Yong-Feng Xue 1, Xue-Jiao Zhang 1, Su-Ting Cao1,2, Zhu-Jun Deng 1, Guiling Li 1, Jianmin Wu 1, Ke-Qing Shi2, Yong-Ping Chen2, Kai-Fu Tang1 *. MicroRNA-581 Promotes Hepatitis B Virus Surface Antigen Expression by Targeting Dicer and EDEM1, Carcinogenesis (In revision). ( IF=5.557)
25 Yan Wang1,2, Lin Chen3, Guiling Li4, Lu lv4, Wei Dai1, Guan Wang5, Enfeng Zhao5, Kai-Fu Tang4*, Zhong Sheng Sun3,4*. Epigenetic Inactivation of Ras-related Associated with Diabetes (RRAD) Promotes Glucose Uptake in a Human Ovarian Cancer Model, J Biol Chem (In revision). IF=5.023.
26 Kai-Fu Tang*, Gui-Li Zeng, Jinfeng Wu and Hong Ren, Idenditifaction and characterization of Dicer-regulated noncoding RNAs, International Drug Discovery Science and Technology (IDDST),(pp 249) Beijing, 2008.10.18-22, Keynote speaker.
27 Kai-Fu Tang*, Histocompatibility (Dicer regulates the expression of major histocompatibility complex (MHC) class I chain-related genes A and B), InTech, (英文專著).
2025考研復(fù)試特訓(xùn)班【1v1個(gè)性批改+模擬面試+聽口糾音】
2025考研復(fù)試伴學(xué)班·【初試不過,協(xié)議退費(fèi)】
溫馨提示: 該信息自網(wǎng)絡(luò)渠道整理,沒有辨別其有效真實(shí)性,若對(duì)本信息有意向,請(qǐng)聯(lián)系院校老師核實(shí)。若有不妥,請(qǐng)聯(lián)系我們刪除。同時(shí)提醒大家,在調(diào)劑復(fù)試階段,一定注意不法分子,在交流過程中涉及金錢等,切勿相信,謹(jǐn)防上當(dāng)受騙。謝謝。 刪除信息請(qǐng)聯(lián)系 tiaoji@163.com
公眾號(hào):考研信息網(wǎng)
查國家線、研究生調(diào)劑
網(wǎng)站介紹 關(guān)于我們 聯(lián)系方式 廣告業(yè)務(wù) 幫助信息
1998-2021 ChinaKaoyan.com Network Studio. All Rights Reserved. 滬ICP備12018245號(hào)